Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: mlkr who wrote (2858)	7/26/2010 11:28:20 AM
From: Jibacoa	Respond to of 3722

BIOD is up 9.57% on volume almost half its ADV bigcharts.marketwatch.com As mentioned. it has reported results of preclinical tests which demonstrated the potential of its glucose-regulated or "smart" basal insulin product candidate, BIOD620, to release insulin proportionally in response to changing glucose conditions.<g> At a meeting in Portland, its director of drug delivery,Nandini Kashyap, described results of in vitro and in vivo studies with diabetic pigs which compared the use of BIOD620 to Lantus. BIOD620 is an injectable formulation of insulin glargine that has been designed to alter its insulin release in response to changing glucose concentration. The drug was able to reduce the elevated plasma glucose levels faster than the group receiving Lantus and post-meal hyperglycemia was also reduced faster than in the control group.<g> The stock is trading above the resistance at the $4 level and is starting to get off from the DT coming from its May16 H at the $6.25 level. bigcharts.marketwatch.com As mentioned, the ACTAY is $15 I would keep a TT at $6 pending further developments. Although with some good news the stock could get to close some of its large DG.<g> The Jan2008 was $25.69 bigcharts.marketwatch.com Bernard